TOP NEWS

Qulab Applies Artificial Intelligence To Drug Design

Los Angeles-based Qulab, a biopharmaceuticals startup developing artifical intelligence software aimed at small molecule drug design, said on Wednesday that it has launched its first product, Quleap. The startup--backed by Cota Capital, Civilization Ventures, Plug and Play, and 415--says that Quleap automated small molecule, synthesis planning, and a cloud engine for simulating biomolecules. Qulab is the brainchild of founder and Cel Alireza Shabani, who most recently was part of the Google Quantum Artificial Intelligence Lab in Los Angeles, and prior to that was a post-doctoral resaercher at Princeton and UC Berkeley. He also attended USC's Viterbi School of Engineering as a Ph.D. According to Quleap, it is looking to make it platform available to scientists in industry and academia, who want to use advanced computing technology for drug and new chemical entity development and discovery.